Single Dose of Psilocybin Shows Promise for Cocaine Addiction in Landmark UAB Trial

Cocaine use disorder has stubbornly resisted pharmaceutical intervention for decades. While medications exist for opioid and alcohol dependence, no FDA-approved pharmacotherapy has demonstrated consistent efficacy for cocaine addiction—until potentially now. A randomized clinical trial conducted at the University of Alabama at Birmingham and published in JAMA Network Open suggests that a single dose of psilocybin, combined with psychotherapy, may fundamentally alter treatment outcomes for this challenging condition.

The study represents a significant methodological and scientific advance. Previous psychedelic research for addiction largely focused on alcohol and tobacco, with cocaine receiving limited attention despite its substantial public health burden. An estimated 25 million people worldwide used cocaine in 2025, with a significant portion developing use disorders that conventional treatment approaches struggle to address.

Breaking New Ground

Lead investigator Peter Hendricks, Ph.D., designed the trial to address two persistent gaps in addiction science: the lack of effective medications for cocaine use disorder and the historical underrepresentation of vulnerable populations in psychedelic research. Of the 40 participants enrolled, 33 were Black, 33 were male, and most reported annual incomes below $20,000—a demographic profile that reflects the communities most affected by cocaine-related harms but least included in clinical research.

"Cocaine use disorder has long lacked effective treatment options, and vulnerable populations have historically been underrepresented in psychedelic research trials," Hendricks noted. "Our clinical trial sought to address these gaps by identifying a possible treatment option while intentionally recruiting individuals from underrepresented communities."

Participants were randomized to receive either a single oral dose of psilocybin—25 milligrams per 70 kilograms of body weight—or an active placebo. Both groups received cognitive behavioral therapy beginning one month before and continuing one month after the investigational drug session. The primary outcomes were assessed at 180 days through structured interviews and urinalysis to verify self-reported abstinence.

Measurable Benefits

The results demonstrated clear advantages for psilocybin-assisted therapy across multiple endpoints. Participants who received the psychedelic compound achieved significantly higher rates of cocaine abstinence compared to those receiving placebo plus psychotherapy. The psilocybin group also showed greater likelihood of complete abstinence and experienced reduced risk of cocaine lapse over the study period.

These findings acquire additional significance when contextualized against the backdrop of existing treatment options. Currently, no medication has demonstrated robust efficacy for cocaine use disorder in large-scale clinical trials. Behavioral interventions remain the standard of care, but relapse rates are high and sustained abstinence remains elusive for many patients. The magnitude of effect observed in this preliminary study suggests psilocybin may offer genuine therapeutic value rather than incremental improvement.

The hypothesis underlying the trial drew on accumulating evidence for psilocybin's anti-addictive properties. Previous research demonstrated efficacy for smoking cessation and alcohol use disorder, suggesting the compound might produce benefits that generalize across substance categories. The current study extends this pattern to stimulant use disorders, potentially broadening the scope of conditions amenable to psychedelic-assisted therapy.

Safety and Tolerability

Adverse events were generally mild and transient. The most common side effect was hypertension, which resolved without intervention. No serious adverse events were attributed to psilocybin administration. These safety data align with the growing body of evidence suggesting that psilocybin, when administered in controlled clinical settings with appropriate screening and support, carries acceptable risk profiles for research and potential therapeutic use.

The study's safety findings are particularly relevant given the historical stigma surrounding psychedelic substances. Demonstrating that psilocybin can be administered safely to individuals with active substance use disorders—population often excluded from clinical trials due to perceived risks—opens possibilities for broader research participation and eventual treatment access.

Mechanistic Questions

How psilocybin produces therapeutic effects remains incompletely understood. The compound's primary pharmacological action involves serotonin 2A receptor agonism, which disrupts default mode network activity and may facilitate cognitive flexibility and perspective shifts. In the context of addiction, these neurobiological effects might help individuals break free from rigid patterns of craving and drug-seeking behavior.

The trial's design—combining a single drug session with structured psychotherapy—reflects the emerging consensus that psychedelic benefits arise from the interaction between biological effects and psychological processing. Participants received preparation before the session and integration afterward, creating a therapeutic container within which the psilocybin experience could be meaningfully incorporated into their recovery process.

Limitations and Next Steps

The study's promising results must be interpreted within acknowledged constraints. The sample size was small—40 participants total—with only 36 completing the full 180-day assessment. The lead author also served as the primary therapist, creating potential for expectancy effects. The study lacked measures to definitively attribute effects to psilocybin rather than psychotherapy alone, though the magnitude of difference between groups suggests a specific drug effect.

Hendricks emphasized the need for continued research employing larger samples across diverse populations. Standardization of therapeutic protocols, improved understanding of the active ingredients in psychedelic-assisted therapy, and replication of findings in multi-site trials will be essential before clinical implementation becomes appropriate.

What This Means for Treatment

For individuals struggling with stimulant addiction, the UAB trial offers hope that new therapeutic options may emerge from unexpected sources. The study joins a growing literature suggesting that psychedelic compounds—substances long associated with recreational use and cultural controversy—may possess genuine clinical utility when deployed within structured therapeutic frameworks.

The research also highlights the importance of inclusive clinical trial design. By intentionally recruiting participants from underrepresented communities, the study demonstrated that rigorous psychedelic research can be conducted with populations historically excluded from such investigations. This inclusivity matters because cocaine use disorder disproportionately affects marginalized communities; treatments developed in homogeneous samples may fail to generalize to those most in need.

Patients and families should recognize that psilocybin remains investigational for cocaine use disorder. While the FDA has granted breakthrough therapy designation for psilocybin in treatment-resistant depression, and recent executive orders have directed federal agencies to prioritize psychedelic research, regulatory approval for addiction indications remains years away. Individuals seeking treatment now should consult addiction specialists about currently available options, including behavioral therapy and contingency management approaches with established efficacy.

Broader Implications

The UAB study arrives at a pivotal moment for psychedelic medicine. Following the FDA's rejection of MDMA-assisted therapy for PTSD in 2024, the field has faced questions about regulatory viability and clinical translation. Positive results for cocaine use disorder—an indication with no existing pharmacotherapy—may help rebuild momentum by demonstrating that psychedelic benefits extend beyond the depression and anxiety applications that have dominated recent research.

The study also contributes to an evolving understanding of addiction neurobiology. Traditional models emphasizing dopamine and reward circuitry have yielded limited therapeutic targets. Psychedelic research suggests that serotonin-mediated processes involving cognitive flexibility, meaning-making, and self-processing may be equally relevant to addiction recovery. This conceptual expansion could inform drug development beyond psychedelics themselves.

As research progresses, the challenge will be translating promising clinical trial results into accessible treatments. Psychedelic-assisted therapy requires specialized training, extended clinical contact, and carefully controlled settings—resources that may be difficult to scale. Finding ways to deliver benefits efficiently while maintaining safety and efficacy will be essential if these findings are to benefit the millions of individuals affected by cocaine use disorder worldwide.